Background {#Sec1}
==========

Peritoneal dialysis (PD) has been established as a successful treatment modality of renal replacement therapy over decades \[[@CR1]\]. However, the mortality of PD patients remains much higher compared to general population, nearly half of which are caused by cardiovascular disease (CVD) \[[@CR2], [@CR3]\]. Numerous risk factors have been identified to be associated with CVD \[[@CR4]--[@CR7]\]. Among them, systemic inflammation is well recognized for its close relationship to cardiovascular morbidity and mortality \[[@CR8]\]. We and others found that elevated C-reactive protein (CRP) levels, especially its elevated trend over time, could be independently predictive of mortality in PD population \[[@CR9]--[@CR11]\]. Importantly, inflammation drives the development of malnutrition, which may in turn amplify systemic inflammation responses, leading to a vicious cycle \[[@CR12], [@CR13]\]. Recently, International Society for Peritoneal Dialysis (ISPD) cardiovascular and metabolic guidelines suggest that PD patients with persistently elevated CRP should be investigated for any treatable cause of inflammation and nutritional status should be assessed within 6--8 weeks after commencement of PD for reducing the risk of CVD mortality \[[@CR2]\]. Therefore, comprehensive assessment of inflammatory and nutritional status will help to identify patients at high risk and are crucial in the management of PD cohorts. However, standardized methods or systems available for this purpose remain to be explored.

Inflammation-based prognostic scores have been developed since last decade and successfully used to monitor patients' status and predict outcomes in cancer management \[[@CR14]--[@CR20]\]. The Glasgow prognostic score (GPS), composed of serum CRP and albumin, has been reported as a powerful predictor for mortality in many cancer patients \[[@CR14]--[@CR16]\]. The prognostic nutritional index (PNI), which was originally developed to monitor nutritional status of perioperative patients, can predict long-term outcomes in patients with a variety of malignancy \[[@CR17]--[@CR19]\]. The prognostic index (PI), based on CRP and white blood cell (WBC) count, has also been shown to be associated with survival in advanced lung cancer patients \[[@CR20]\]. However, few studies have investigated the association of these composite scores with outcomes in continuous ambulatory peritoneal dialysis (CAPD) patients. Therefore, the purpose of this study was to evaluate the prognostic values of these scores in CAPD patients.

Methods {#Sec2}
=======

Study participants {#Sec3}
------------------

Patients were enrolled from PD center of The First Affiliated Hospital of Sun Yat-sen University from January 1, 2006 to December 31, 2014. Patients who had received CAPD for more than 3 months were included. Patients who were younger than 18 years old, undergone CAPD for less than 3 months, transferred from hemodialysis (HD), with a history of renal transplantation or malignancy before PD, or without data of serum CRP, albumin, or WBC count, were excluded from this study. The study was approved by the Ethics Committee of The First Affiliated Hospital of Sun Yat-sen University. All participants provided their written informed consent for this study.

Data collection and laboratory measurements {#Sec4}
-------------------------------------------

This work was a retrospective cohort study. Baseline demographic and clinical data, including age, gender, a history of smoke, diabetes, hypertension, cardiovascular disease, were collected at the start of CAPD treatment. Diabetes and hypertension were recorded as previously defined \[[@CR21]\]. Baseline biochemical parameters were collected 1--3 months after the initiation of PD therapy, including blood pressure (BP), hemoglobin, WBC count, serum CRP, albumin, total triglycerides, total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), uric acid, and creatinine. Residual renal function, in ml/min/1.73m^2^, was estimated from mean values of creatinine clearance and urea clearance and adjusted for body surface area calculated with the Gehan and George equation \[[@CR6]\]. All measurements of biochemical parameters were performed in the biochemical laboratory of The First Affiliated Hospital of Sun Yat-sen University. The constituents of three inflammation-based prognostic scores (GPS, PNI and PI) were listed in Table [1](#Tab1){ref-type="table"}.Table 1Inflammation-based prognostic scoresScoring systemsScoreGPS CRP ≤ 10 mg/L and ALB ≥ 35 g/L0 CRP \> 10 mg/L or ALB \< 35 g/L1 CRP \> 10 mg/L and ALB \< 35 g/L2PNI 10 × serum albumin value (g/dl) + 0.005 × peripheral lymphocyte count (/ul) ≥ 450 10 × serum albumin value (g/dl) + 0.005 × peripheral lymphocyte count (/ul) \< 451PI CRP ≤ 10 mg/L and WBC ≤ 11 × 10^9^/L0 CRP ≤10 mg/L and WBC \> 11 × 10^9^/L1 CRP \> 10 mg/L and WBC ≤ 11 × 10^9^/L1 CRP \> 10 mg/L and WBC \> 11 × 10^9^/L2Abbreviations: *GPS* Glasgow Prognostic Score, *CRP* C-reactive protein, *ALB* albumin, *PNI* prognostic nutritional index, *PI* prognostic index, *WBC* white blood cell

Outcomes {#Sec5}
--------

The primary endpoint of this study was all-cause mortality, and the second endpoint was CVD mortality. CVD mortality was defined as death caused by events including acute myocardial infarction, cardiac arrhythmia, congestive heart failure, atherosclerotic heart disease, cardiomyopathy, cardiac arrest, intracranial hemorrhage, cerebral infarction and peripheral vascular disease \[[@CR22]\]. All participants were followed up until death, cessation of PD, or December 31, 2016.

Statistical analysis {#Sec6}
--------------------

The data were presented as mean ± standard deviation for normally distributed continuous variables, median (interquartile range) for skewed continuous variables, and number (proportion) for categorical variables. The Kaplan-Meier curve was used to calculate survival rate followed by log-rank test to compare differences among groups. Univariate and multivariate Cox proportional hazards models were used to analyze the associations between prognostic scores and all-cause and CVD mortality. The multivariate Cox regression model was constructed by adjusting covariates using a backward stepwise selection procedure with a stay criterion of 0.10 (the selection cut-off value was from default in SPSS software system as well as the importance of clinical concern). Receiver-operating characteristic (ROC) analysis was performed and the area under the curve (AUC) was calculated to determine the predictive power of prognostic scores for mortality. Comparison of AUC values among groups was determined using MedCalc software version 15.0 (Broekstraat, Mariakerke, Belgium) \[[@CR23]\]. All other statistical analyses were performed using SPSS version 22.0 for Windows (SPSS, Chicago, IL, USA). *P* \< 0.05 was considered statistically significant using two-tailed tests.

Results {#Sec7}
=======

Baseline demographic and clinical characteristics {#Sec8}
-------------------------------------------------

Baseline demographic and clinical characteristics of the cohort study are given in Table [2](#Tab2){ref-type="table"}. A total of 1501 eligible CAPD patients were included in this study. The mean age was 46.4 ± 15.1 years, 59.1% were male, 21.7% had a history of diabetes mellitus. The leading cause of ESRD was primary glomerulonephritis (928, 61.8%), followed by diabetic nephropathy (292, 19.5%), hypertension (135, 9.0%) and others (146, 9.7%). The median vintage of PD was 38.7 (range, 21.6--62.3) months.Table 2Baseline characteristics of 1501 CAPD patientsCharacteristicsValuesAge (years)46.4 ± 15.1Gender (Male)887 (59.1%)Smoke253 (16.9%)Body mass index (kg/m^2^)21.5 ± 3.7Systolic BP (mmHg)136.2 ± 20.6Diastolic BP (mmHg)84.9 ± 14.4Hypertension605 (40.3%)Diabetes mellitus326 (21.7%)Cardiovascular disease249 (16.6%)Serum albumin (g/L)36.4 ± 5.0Calcium (mmol/L)2.2 ± 0.3Phosphorus (mmol/L)1.7 ± 0.6iPTH (pg/mL)289.0 (144.4--455.5)CRP (mg/L)1.6 (0.8--5.5)WBC (× 10^9^/L)6.9 ± 2.4Lymphocyte (× 10^9^//L)1.4 ± 0.6Hemoglobin (g/L)89.8 ± 22.8Total cholesterol (mmol/L)5.1 ± 1.4Total triglycerides (mmol/L)1.6 ± 1.1HDL-C (mmol/L)1.2 ± 0.4LDL-C (mmol/L)3.0 ± 1.1Plasma uric acid (μmol/L)430.3 ± 101.0Plasma creatinine (μmol/L)766.7 ± 277.5RRF (ml/min/1.73m^2^)3.7 ± 3.0Abbreviations: *CAPD* continuous ambulatory peritoneal dialysis, *BP* blood pressure, *iPTH* intact parathyroid hormone, *CRP* C-reactive protein, *WBC* white blood cell, *HDL-C* high-density lipoprotein cholesterol, *LDL-C* low-density lipoprotein cholesterol, *RRF* residual renal function

During the follow-up period, 318 (21.2%) patients underwent renal transplantation, 185 (12.3%) were transferred to HD, 59 (3.9%) were transferred to other centers, 36 (2.4%) were lost to follow-up, and finally, 903 (60.2%) were followed up until the end of the study.

Inflammation-based prognostic scores {#Sec9}
------------------------------------

According to the GPS scoring system, 909 (60.6%) of the 1501 patients showed a score of 0, while 456 (30.4%) and 136 (9.1%) patients had a score of 1 and 2, respectively. PNI classification revealed that 897 (59.8%) patients had a score of 1. With regard to PI, there were 253 (16.9%) and 35 (2.3%) patients who displayed a score of 1 and 2, respectively. In mortality population, larger proportions of patients were categorized into higher score groups (Table [3](#Tab3){ref-type="table"}). Compared with non-diabetic patients, diabetic patients presented with higher scores (Table [4](#Tab4){ref-type="table"}).Table 3Distribution of inflammation-based prognostic scores among groupsPrognostic scoreAll patients (*n* = 1501)Survival patients (*n* = 1155)All-cause mortality (*n* = 346)CVD mortality (*n* = 168)GPS 0909 (60.6%)845 (73.2%)64 (18.5%)26 (15.5%) 1456 (30.4%)272 (23.5%)184 (53.2%)89 (53.0%) 2136 (9.1%)38 (3.3%)98 (28.3%)53 (31.5%)PNI 0604 (40.2%)537 (46.5%)67 (19.4%)29 (17.3%) 1897 (59.8%)618 (53.5%)279 (80.6%)139 (82.7%)PI 01213 (80.8%)1016 (88.0%)197 (56.9%)89 (53.0%) 1253 (16.9%)130 (11.3%)123 (35.6%)68 (40.5%) 235 (2.3%)9 (0.8%)26 (7.5%)11 (6.5%)Abbreviations: *GPS* Glasgow Prognostic Score, *PNI* prognostic nutritional index, *PI* prognostic index, *CVD* cardiovascular diseaseTable 4Comparison of inflammation-based prognostic scores between diabetic and non-diabetic patientsPrognostic scoreAll patients (*n* = 1501)Diabetic patients (*n* = 326)Non-diabetic Patients (*n* = 1175)*P* valueGPS 0909 (60.6%)104 (31.9%)805 (68.5%)\< 0.001 1456 (30.4%)175 (53.7%)281 (23.9%) 2136 (9.1%)47 (14.4%)89 (7.6%)PNI 0604 (40.2%)75 (23.0%)529 (45.0%)\< 0.001 1897 (59.8%)251 (71.0%)646 (55.0%)PI 01213 (80.8%)233 (71.5%)980 (83.4%)\< 0.001 1253 (16.9%)79 (24.2%)174 (14.8%) 235 (2.3%)14 (4.3%)21 (1.8%)Abbreviations: *GPS* Glasgow Prognostic Score, *PNI* prognostic nutritional index, *PI* prognostic index, *CVD* cardiovascular disease

Patient survival {#Sec10}
----------------

A total of 346 deaths (23.1%) occurred, of which 168 (48.6%) were attributed to CVD (Fig. [1](#Fig1){ref-type="fig"}). Kaplan-Meier analyses indicated that the cumulative overall survival rates of patients with a GPS score of 0, 1, 2, were 93.0%, 59.6%, 27.9%, respectively (log-rank test, *P* \< 0.001); the CVD survival rates were also significantly lower in patients with higher scores (score 1: 80.5%; score 2: 61.0%) than those with a score of 0 (97.1%) (log-rank test, *P* \< 0.001). Elevated PNI and PI scores were also shown to be associated with reduced all-cause and CVD survival rates (Fig. [2](#Fig2){ref-type="fig"}).Fig. 1Flowchart of the patient selection process. Abbreviations: CRP, C-reactive protein; WBC, white blood cell; PD, peritoneal dialysis; HD, hemodialysis; CVD, cardiovascular diseaseFig. 2Kaplan--Meier estimates of cumulative overall (**a**, **c**, **e**) and CVD-free (**b**, **d**, **f**) survival rate according to different prognostic scores. Abbreviations: CVD, cardiovascular disease; GPS, Glasgow Prognostic Score; PNI, prognostic nutritional index; PI, prognostic index

Univariate cox hazards analysis revealed that increased GPS, PNI and PI scores were all significantly related to all-cause and CVD mortality (Table [5](#Tab5){ref-type="table"}). After adjusting for covariates including age, BP, diabetes, hypertension, cardiovascular disease, infection, hemoglobin, total triglycerides, total cholesterol, LDL-C, HDL-C, uric acid, and creatinine, the patients with increased GPS scores still had a significant increased risk for overall \[Score 1: hazard ratio(HR) 3.94, 95% confidence interval(CI) 2.90--5.35, *P* \< 0.001; Score 2: HR 7.56, 95% CI 5.35--10.67, *P* \< 0.001\] and CVD mortality (Score 1: HR 4.41, 95% CI 2.76--7.03,*P* \< 0.001; Score 2: HR 9.64, 95% CI 5.72--16.26, *P* \< 0.001). Increased PNI and PI values were also independently predictive of all-cause and CVD mortality (Table [6](#Tab6){ref-type="table"}).Table 5Univariate cox proportional analysis for all-cause and CVD mortalityUnivariate (All-cause mortality)Univariate (CVD mortality)HR (95%CI)*P* valueHR (95%CI)*P* valueAge1.06 (1.05--1.07)\< 0.0011.07 (1.06--1.08)\< 0.001Gender (Male)0.92 (0.74--1.13)0.4290.96 (0.71--1.30)0.790Smoke1.16 (0.88--1.52)0.3001.18 (0.80--1.73)0.401Body mass index(kg/m^2^)1.06 (1.03--1.09)\< 0.0011.07 (1.03--1.12)0.002Systolic BP (mmHg)1.01 (1.00--1.01)0.0131.01 (1.00--1.02)0.003Diastolic BP (mmHg)0.98 (0.97--0.98)\< 0.0010.98 (0.97--0.99)\< 0.001Hypertension2.86 (2.29--3.56)\< 0.0013.92 (2.81--5.48)\< 0.001Diabetes mellitus3.35 (2.71--4.14)\< 0.0014.45 (3.29--6.03)\< 0.001Cardiovascular disease3.54 (2.84--4.43)\< 0.0014.96 (3.65--6.73)\< 0.001Infection3.46 (2.43--4.94)\< 0.0012.64 (1.50--4.66)0.001Residual renal function0.97 (0.92--1.01)0.120.94 (0.88--1.01)0.09Calcium (mmol/L)0.31 (0.21--0.45)\< 0.0010.28 (0.16--0.49)\< 0.001Phosphorus (mmol/L)1.01 (0.85--1.20)0.9020.94 (0.73--1.20)0.610iPTH (pg/mL)1.00 (1.00--1.00)0.2291.00 (1.00--1.00)0.626Hemoglobin (g/L)0.99 (0.99--1.00)0.0010.99 (0.98--0.99)\< 0.001Total cholesterol (mmol/L)1.04 (0.97--1.13)0.2571.12 (1.02--1.23)0.022Total triglycerides (mmol/L)1.12 (1.03--1.21)0.0081.16 (1.04--1.29)0.007HDL-C (mmol/L)0.58 (0.44--0.77)\< 0.0010.62 (0.42--0.93)0.021LDL-C (mmol/L)1.05 (0.95--1.16)0.3411.12 (0.99--1.28)0.070Serum uric acid (μmol/L)1.00 (1.00--1.00)0.0691.00 (1.00--1.00)0.007Serum creatinine (μmol/L)1.00 (1.00--1.00)\< 0.0011.00 (1.00--1.00)\< 0.001GPS 0referenceReference 16.37 (4.79--8.48)\< 0.0017.46 (4.81--11.56)\< 0.001 214.66 (10.68--20.13)\< 0.00119.09 (11.91--30.57)\< 0.001PNI 0referenceReference 12.84 (2.17--3.70)\< 0.0013.27 (2.19--4.88)\< 0.001PI 0referenceReference 13.48 (2.78--4.37)\< 0.0014.26 (3.10--5.85)\< 0.001 25.29 (3.51--7.98)\< 0.0015.08 (2.71--9.53)\< 0.001Abbreviations: *HR* hazard ratio, *CI* confidence interval, *CAPD* continuous ambulatory peritoneal dialysis, *BP* blood pressure, *iPTH* intact parathyroid hormone, *CRP* C-reactive protein, *WBC* white blood cell, *HDL-C* high-density lipoprotein cholesterol, *LDL-C* low-density lipoprotein cholesterol, *RRF* residual renal function, *GPS* Glasgow Prognostic Score, *PNI* prognostic nutritional index, *PI* prognostic index, *CVD* cardiovascular diseaseTable 6Multivariate cox proportional analysis for all-cause and CVD mortalityMultivariate (All-cause mortality)Multivariate (CVD mortality)HR (95%CI)*P* valueHR (95%CI)*P* valueGPS 0referenceReference 13.94 (2.90--5.35)\< 0.0014.41 (2.76--7.03)\< 0.001 27.56 (5.35--10.67)\< 0.0019.64 (5.72--16.26)\< 0.001PNI 0Referencereference 11.82 (1.36--2.43)\< 0.0011.63 (1.06--2.51)0.027PI 0referencereference 12.08 (1.63--2.65)\< 0.0012.57 (1.81--3.66)\< 0.001 23.03 (2.00--4.60)\< 0.0013.85 (1.99--7.46)\< 0.001Adjustments were made for variables from the predictor variables of Table [5](#Tab5){ref-type="table"} using a backward stepwise cox proportional hazards model with a stay criterion of 0.10Abbreviations: *GPS* Glasgow Prognostic Score, *PNI* prognostic nutritional index, *PI* prognostic index, *CVD* cardiovascular disease

Comparison of prognostic values of inflammation-based scores {#Sec11}
------------------------------------------------------------

When all-cause mortality was used as an endpoint, the area under the curve (AUC) was 0.798 (95% CI 0.770--0.826, *P* \< 0.001) for GPS, 0.636 (95% CI 0.604--0.667, *P* \< 0.001) for PNI, 0.658 (95% CI 0.622--0.694, *P* \< 0.001) for PI. The AUC values for CVD mortality were 0.781 (95% CI 0.744--0.817, *P* \< 0.001) for GPS, 0.629 (95% CI 0.589--0.670, *P* \< 0.001) for PNI and 0.658 (95% CI 0.609--0.706, *P* \< 0.001) for PI. By comparison of AUC values among groups, the GPS score showed a better distinguishing power for predicting all-cause and CVD mortality compared with PNI and PI (*P* \< 0.001, respectively) (Fig. [3](#Fig3){ref-type="fig"} & Table [7](#Tab7){ref-type="table"}).Fig. 3ROC curve of prognostic scores for mortalityTable 7Area under the ROC curve of prognostic scores for all-cause and CVD mortalityPrognostic scoreArea under the ROC curve95% CI*P* value (vs. GPS)All-cause mortality GPS0.7980.770--0.826 PNI0.6360.604--0.667\< 0.001 PI0.6580.622--0.694\< 0.001CVD mortality GPS0.7810.744--0.817 PNI0.6290.589--0.670\< 0.001 PI0.6580.609--0.706\< 0.001Abbreviations: *ROC* receiver-operating characteristic analysis, *HR* hazard ratio, *CI* confidence interval, *CAPD* continuous ambulatory peritoneal dialysis, *BP* blood pressure, *iPTH* intact parathyroid hormone, *CRP* C-reactive protein, *WBC* white blood cell, *HDL-C* high-density lipoprotein cholesterol, *LDL-C* low-density lipoprotein cholesterol, *RRF* residual renal function, *GPS* Glasgow Prognostic Score, *PNI* prognostic nutritional index, *PI* prognostic index, *CVD* cardiovascular disease

Discussion {#Sec12}
==========

In this retrospective cohort study of 1501 CAPD patients with a median follow-up of 38.7 months, we demonstrated that increased GPS, PNI, and PI scores were all significantly related to all-cause and CVD mortality after adjustment for confounders. ROC analysis indicated that GPS had the best predictive value among these three scores system for CAPD patients.

Inflammation is prevalent in PD patients \[[@CR8]\]. Besides acute episodes of peritonitis, micro-inflammation also constitutes an important component of systemic inflammation responses \[[@CR8], [@CR9], [@CR12]\]. Micro-inflammation in PD patients may be attributed to accumulation of uremic toxins, catheter implantation, bioincompatible dialysis solution, and so on \[[@CR8]\]. Infections in the occult areas may also play a role, such as periodontal problems \[[@CR24]\]. Systemic inflammation status is closely related to malnutrition and atherosclerosis. These three factors interrelate with each other and form a vicious cycle, eventually leading to increased cardiovascular morbidity and mortality \[[@CR9], [@CR12], [@CR13]\]. In our study, although a minor population (62/1501) had active infection during data collection period, most patients did not present obvious signs of infection. The median level of CRP of the whole cohort was in the normal range, which may support the importance of micro-inflammation.

GPS, comprising CRP and serum albumin, is a concise prognostic score that may reflect presence of both the systemic inflammatory response and deteriorating nutritional status. Inamoto et al. found the GPS was an independent prognostic factor for cancer-specific survival and overall survival after surgery with curative intent for localized upper tract urothelial carcinoma \[[@CR10]\]. A study based on regular HD patients showed that elevated GPS was independently predictive of all-cause mortality and hospitalization during 42-month follow-up \[[@CR25]\]. Consistent to these reports, our results showed that raised GPS values consistently related to both overall and CVD mortality in CAPD patients. The strong power for outcome prediction of this score may be attributed to the combined effects of its components. Both markers, CRP and serum albumin, have been demonstrated to be strongly associated with all-cause and CVD mortality in patients on PD \[[@CR9]--[@CR11], [@CR26], [@CR27]\]. However, ROC analysis revealed that GPS had the higher value than hypoalbuminemia or increased CRP alone (data not shown), which may indicate a reciprocal interaction between these two factors.

The PNI score, which is based on serum albumin and total lymphocyte count, has been developed mainly to assess the nutritional status of patients \[[@CR17]--[@CR19]\]. In this study we found that elevated PNI score was independently associated with increased risk for overall and CVD mortality in CAPD patients. To our knowledge, another 2 studies have explored the predictive effect of PNI in PD cohorts \[[@CR28], [@CR29]\]. One study was limited to Korean subjects and showed that the PNI score was significantly related to all-cause mortality in PD patients, which is in agreement with our result \[[@CR28]\]. The other study reported that PNI was associated with increased risk for CVD mortality but not all-cause mortality in 345 Chinese PD patients, which is partly conflicting with our findings \[[@CR29]\]. The discrepancy may be due to differences in sample size, definition of PNI thresholds, or confounders chosen for adjustment. The PI score is composed of CRP and WBC count and has been validated as a useful predictive factor in lung and colon cancer \[[@CR20], [@CR30]\]. It is also suggested that PI was related to all-cause mortality in patients on regular HD \[[@CR24]\]. Our study added new evidence that elevated PI scores were also independently predictive of overall and CVD mortality in a large population of CAPD patients.

The prognostic values of these prognostic scores in CAPD patients were compared in our study. Results indicated that the GPS consistently exhibited a higher AUC value compared with PNI and PI scores and showed an excellent discriminatory performance for the CAPD patients. These findings were consistent with Akihiko's report \[[@CR24]\], in which the GPS score had the best predictive power for prognosis of HD patients. The GPS score was a combination of suitable markers for inflammation and malnutrition, while the other two were inclined to isolated aspects. These comparisons thus imply that a comprehensive monitor of both inflammatory and nutritional status may help better improve outcomes in dialysis patients. In addition, these inflammation-based prognostic scores consist of components which are routinely available with low cost.

There are some limitations in the present study. Firstly, this was a retrospective study conducted in one single center and may thus have potential selection bias. Secondly, a large number of patients without certain blood test results were excluded, making those enrolled may not be well representative for the PD population. Thirdly, we calculated the values of these scoring systems at baseline, while a time-averaged score may be better for outcome prediction. Last but not the least, a minor population of patients with active infection were included in our cohort. Although our results showed the existence of infection did not affect the prognostic significance of scoring systems, we could not exclude the possibility of other confounding effects that deranged CRP or albumin levels during infection may produce.

Conclusions {#Sec13}
===========

In conclusion, the present study demonstrated that three well-standardized prognostic scores, GPS, PNI, and PI, are all independently associated with all-cause and CVD mortality in CAPD patients. In particularly, the GPS score shows the better predictive power for mortality compared to the other two scores. The GPS score may thus represent a simple and feasible tool for outcome prediction in CAPD patients.
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